|
1
|
Interlaboratory comparison of results of susceptibility testing with caspofungin against Candida and Aspergillus species.
|
J Clin Microbiol
|
2004
|
4.70
|
|
2
|
In vitro activities of posaconazole, itraconazole, voriconazole, amphotericin B, and fluconazole against 37 clinical isolates of zygomycetes.
|
Antimicrob Agents Chemother
|
2002
|
2.89
|
|
3
|
Disseminated phaeohyphomycosis: review of an emerging mycosis.
|
Clin Infect Dis
|
2002
|
2.70
|
|
4
|
Infections caused by Scedosporium spp.
|
Clin Microbiol Rev
|
2008
|
2.69
|
|
5
|
Primary central nervous system phaeohyphomycosis: a review of 101 cases.
|
Clin Infect Dis
|
2003
|
2.62
|
|
6
|
Experimental pulmonary aspergillosis due to Aspergillus terreus: pathogenesis and treatment of an emerging fungal pathogen resistant to amphotericin B.
|
J Infect Dis
|
2003
|
2.45
|
|
7
|
Sequence-based identification of filamentous basidiomycetous fungi from clinical specimens: a cautionary note.
|
J Clin Microbiol
|
2009
|
2.44
|
|
8
|
Molecular phylogenetic diversity, multilocus haplotype nomenclature, and in vitro antifungal resistance within the Fusarium solani species complex.
|
J Clin Microbiol
|
2008
|
2.16
|
|
9
|
Genetic diversity of human pathogenic members of the Fusarium oxysporum complex inferred from multilocus DNA sequence data and amplified fragment length polymorphism analyses: evidence for the recent dispersion of a geographically widespread clonal lineage and nosocomial origin.
|
J Clin Microbiol
|
2004
|
2.13
|
|
10
|
In vitro susceptibilities of 217 clinical isolates of zygomycetes to conventional and new antifungal agents.
|
Antimicrob Agents Chemother
|
2007
|
1.85
|
|
11
|
Development and validation of a high-performance liquid chromatography assay for voriconazole.
|
Antimicrob Agents Chemother
|
2003
|
1.77
|
|
12
|
In vitro interaction of caspofungin acetate with voriconazole against clinical isolates of Aspergillus spp.
|
Antimicrob Agents Chemother
|
2002
|
1.65
|
|
13
|
Zygomycosis.
|
Infect Dis Clin North Am
|
2002
|
1.58
|
|
14
|
The role of antifungal susceptibility testing in the therapy of candidiasis.
|
Diagn Microbiol Infect Dis
|
2004
|
1.58
|
|
15
|
Pseudallescheria boydii (Anamorph Scedosporium apiospermum). Infection in solid organ transplant recipients in a tertiary medical center and review of the literature.
|
Medicine (Baltimore)
|
2002
|
1.53
|
|
16
|
Internet-accessible DNA sequence database for identifying fusaria from human and animal infections.
|
J Clin Microbiol
|
2010
|
1.51
|
|
17
|
Molecular phylogenetic diversity of the emerging mucoralean fungus Apophysomyces: proposal of three new species.
|
Rev Iberoam Micol
|
2010
|
1.40
|
|
18
|
Posaconazole therapeutic drug monitoring: a reference laboratory experience.
|
Antimicrob Agents Chemother
|
2009
|
1.31
|
|
19
|
Taxonomy and phylogeny of the Fusarium dimerum species group.
|
Mycologia
|
2009
|
1.24
|
|
20
|
Novel multilocus sequence typing scheme reveals high genetic diversity of human pathogenic members of the Fusarium incarnatum-F. equiseti and F. chlamydosporum species complexes within the United States.
|
J Clin Microbiol
|
2009
|
1.22
|
|
21
|
Trichosporon mycotoxinivorans, a novel respiratory pathogen in patients with cystic fibrosis.
|
J Clin Microbiol
|
2009
|
1.14
|
|
22
|
Candida glabrata oropharyngeal candidiasis in patients receiving radiation treatment for head and neck cancer.
|
J Clin Microbiol
|
2002
|
1.14
|
|
23
|
In vitro activities of new and established triazoles against opportunistic filamentous and dimorphic fungi.
|
Med Mycol
|
2005
|
1.11
|
|
24
|
Two new species of Mucor from clinical samples.
|
Med Mycol
|
2010
|
1.05
|
|
25
|
Accelerated metabolism of voriconazole and its partial reversal by cimetidine.
|
Antimicrob Agents Chemother
|
2009
|
1.05
|
|
26
|
Scedosporium prolificans brain abscess in a patient with chronic granulomatous disease: successful combination therapy with voriconazole and terbinafine.
|
Scand J Infect Dis
|
2007
|
1.02
|
|
27
|
Molecular mycological diagnosis and correct antimycotic treatments.
|
J Clin Microbiol
|
2005
|
1.02
|
|
28
|
Caspofungin in combination with amphotericin B against Candida glabrata.
|
Antimicrob Agents Chemother
|
2005
|
0.98
|
|
29
|
In vitro activities of new antifungal agents against Chaetomium spp. and inoculum standardization.
|
Antimicrob Agents Chemother
|
2003
|
0.98
|
|
30
|
Paecilomyces lilacinus vaginitis in an immuno-competent patient.
|
Emerg Infect Dis
|
2003
|
0.97
|
|
31
|
In vitro and in vivo activities of posaconazole and amphotericin B in a murine invasive infection by Mucor circinelloides: poor efficacy of posaconazole.
|
Antimicrob Agents Chemother
|
2012
|
0.95
|
|
32
|
Posaconazole prophylaxis in experimental systemic zygomycosis.
|
Antimicrob Agents Chemother
|
2006
|
0.94
|
|
33
|
Candida glabrata is an emerging cause of oropharyngeal candidiasis in patients receiving radiation for head and neck cancer.
|
Oral Surg Oral Med Oral Pathol Oral Radiol Endod
|
2004
|
0.94
|
|
34
|
In vitro antifungal susceptibility and molecular characterization of clinical isolates of Fusarium verticillioides (F. moniliforme) and Fusarium thapsinum.
|
Antimicrob Agents Chemother
|
2008
|
0.93
|
|
35
|
In vitro activities of terbinafine in combination with fluconazole, itraconazole, voriconazole, and posaconazole against clinical isolates of Candida glabrata with decreased susceptibility to azoles.
|
J Clin Microbiol
|
2002
|
0.93
|
|
36
|
Scedosporium apiospermum soft tissue infection successfully treated with voriconazole: potential pitfalls in the transition from intravenous to oral therapy.
|
J Clin Microbiol
|
2005
|
0.93
|
|
37
|
In vitro activities of free and lipid formulations of amphotericin B and nystatin against clinical isolates of Coccidioides immitis at various saprobic stages.
|
Antimicrob Agents Chemother
|
2002
|
0.90
|
|
38
|
Pharmacokinetics of liposomal amphotericin B in pleural fluid.
|
Antimicrob Agents Chemother
|
2010
|
0.89
|
|
39
|
In vitro activities of voriconazole in combination with three other antifungal agents against Candida glabrata.
|
Antimicrob Agents Chemother
|
2004
|
0.88
|
|
40
|
Activity of posaconazole against Pseudallescheria boydii: in vitro and in vivo assays.
|
Antimicrob Agents Chemother
|
2003
|
0.88
|
|
41
|
Cutaneous infection caused by Macrophomina phaseolina in a child with acute myeloid leukemia.
|
J Clin Microbiol
|
2009
|
0.88
|
|
42
|
Office practice-based confirmation of onychomycosis: a US nationwide prospective survey.
|
Arch Intern Med
|
2002
|
0.88
|
|
43
|
Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice.
|
Antimicrob Agents Chemother
|
2010
|
0.87
|
|
44
|
Micafungin concentrations from brain tissue and pancreatic pseudocyst fluid.
|
Antimicrob Agents Chemother
|
2009
|
0.87
|
|
45
|
Persistent pulmonary infection with an azole-resistant Coccidioides species.
|
Med Mycol
|
2008
|
0.87
|
|
46
|
Evaluation of aminocandin and caspofungin against Candida glabrata including isolates with reduced caspofungin susceptibility.
|
J Antimicrob Chemother
|
2008
|
0.87
|
|
47
|
Antifungal susceptibility testing of Exophiala spp.: a head-to-head comparison of amphotericin B, itraconazole, posaconazole and voriconazole.
|
Med Mycol
|
2008
|
0.87
|
|
48
|
Disseminated mycotic infection caused by Colletotrichum acutatum in a Kemp's ridley sea turtle (Lepidochelys kempi).
|
J Clin Microbiol
|
2002
|
0.86
|
|
49
|
Oropharyngeal candidiasis caused by non-albicans yeast in patients receiving external beam radiotherapy for head-and-neck cancer.
|
Int J Radiat Oncol Biol Phys
|
2003
|
0.86
|
|
50
|
Multicenter comparison of the Vitek 2 antifungal susceptibility test with the CLSI broth microdilution reference method for testing caspofungin, micafungin, and posaconazole against Candida spp.
|
J Clin Microbiol
|
2011
|
0.84
|
|
51
|
Relationship between metabolism and biomass of medically important zygomycetes.
|
Med Mycol
|
2006
|
0.84
|
|
52
|
Outbreak of invasive Aspergillus infection in surgical patients, associated with a contaminated air-handling system.
|
Clin Infect Dis
|
2003
|
0.83
|
|
53
|
Efficacy of caspofungin against Aspergillus terreus.
|
Antimicrob Agents Chemother
|
2005
|
0.83
|
|
54
|
Enteral fluconazole is well absorbed in critically ill surgical patients.
|
Surgery
|
2002
|
0.81
|
|
55
|
Pharmacokinetics of anidulafungin in pleural fluid during the treatment of a patient with Candida empyema.
|
Antimicrob Agents Chemother
|
2011
|
0.81
|
|
56
|
Combination therapy with terbinafine and amphotericin B in a rabbit model of experimental invasive aspergillosis.
|
Antimicrob Agents Chemother
|
2005
|
0.80
|
|
57
|
Comparison of the Vitek 2 yeast susceptibility system with CLSI microdilution for antifungal susceptibility testing of fluconazole and voriconazole against Candida spp., using new clinical breakpoints and epidemiological cutoff values.
|
Diagn Microbiol Infect Dis
|
2013
|
0.80
|
|
58
|
Enteral fluconazole population pharmacokinetics in patients in the surgical intensive care unit.
|
Pharmacotherapy
|
2003
|
0.79
|
|
59
|
Efficacies of amphotericin B (AMB) lipid complex, AMB colloidal dispersion, liposomal AMB, and conventional AMB in treatment of murine coccidioidomycosis.
|
Antimicrob Agents Chemother
|
2004
|
0.77
|
|
60
|
Are epidemiologic cut-off values predictors of the in vivo efficacy of azoles in experimental aspergillosis?
|
Diagn Microbiol Infect Dis
|
2012
|
0.77
|
|
61
|
Confirmation of dermatophytes in nail specimens using in-office dermatophyte test medium cultures. Insights from a multispecialty survey.
|
J Am Podiatr Med Assoc
|
2003
|
0.77
|
|
62
|
Antifungal susceptibility testing.
|
Infect Dis Clin North Am
|
2006
|
0.77
|
|
63
|
Cutaneous infection with Metarhizium anisopliae in a patient with hypohidrotic ectodermal dysplasia and immune deficiency.
|
Pediatr Infect Dis J
|
2008
|
0.76
|
|
64
|
Evaluation of the correlation of caspofungin MICs and treatment outcome in murine infections by wild type strains of Candida parapsilosis.
|
Diagn Microbiol Infect Dis
|
2013
|
0.76
|
|
65
|
MIC values of voriconazole are predictive of treatment results in murine infections by Aspergillus terreus species complex.
|
Antimicrob Agents Chemother
|
2013
|
0.76
|
|
66
|
Cerebral aspergillosis caused by Aspergillus granulosus.
|
J Clin Microbiol
|
2009
|
0.75
|
|
67
|
Total synthesis and antifungal activity of a carbohydrate ring-expanded pyranosyl nucleoside analogue of nikkomycin B.
|
J Org Chem
|
2007
|
0.75
|
|
68
|
Studies on peptidyl nucleoside antibiotics: synthesis and antifungal evaluation of pyranosyl nucleoside analogs of nikkomycin.
|
Future Med Chem
|
2009
|
0.75
|
|
69
|
Steady-state plasma concentrations of itraconazole after oral administration in Kemp's ridley sea turtles, Lepidochelys kempi.
|
J Zoo Wildl Med
|
2003
|
0.75
|
|
70
|
Clinical research in the lay press: irresponsible journalism raises a huge dose of doubt.
|
Clin Infect Dis
|
2006
|
0.75
|